Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Update on Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed

Streetwise Reports, Streetwise Reports
0 Comments| October 30, 2018

{{labelSign}}  Favorites
{{errorMessage}}

Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed.

Click to enlarge

You may recall that we looked at this stock, Avivagen Inc. (VIV:TSX.V), almost a month ago, which is in the vanguard of the drive to phase out antibiotics in animal feed. Since that time, although the price has moved little, the stock has continued to strengthen, and most importantly, it has been impervious to the crashing stock market, which doesn't seem to have affected it at all.

The purpose of this update is to draw your attention to this and also to the fact that it appears to be getting ready to break out to the upside, which could happen at any time now. On the 6-month chart below we can see that it is at the point of breaking out above the downtrend line shown, and more importantly from the large bullish Falling Wedge that may readily be seen on the 3-month chart, which was included in the original report on it posted on September 30th. On the chart below we can see heavy buying showing up again about a week ago, which has driven both volume indicators higher again—this is very bullish volume action and suggests that breakout is drawing near.

Click to enlarge

We therefore stay long, and it is rated an immediate strong buy here.

Avivagen Inc website

Avivagen Inc, VIV.V, CHEXF on OTC, closed at C$0.60, $0.40 on 26th October 2018./p>

Clive Maund has been president of www.clivemaund.com, a successful resource sector website, since its inception in 2003. He has 30 years' experience in technical analysis and has worked for banks, commodity brokers and stockbrokers in the City of London. He holds a Diploma in Technical Analysis from the UK Society of Technical Analysts.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company